Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Deal Origination Executive Search For Sales Teams Corporate Development For Founders For Agencies For Investors Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Start Free
CuroNZ logo — Innovative biotech with CNS clinical drug

CuroNZ

Innovative biotech with CNS clinical drug

Founded 2010 New Zealand New Zealand 3 employees

General Information

Company Name CuroNZ
Founded Year 2010
Location New Zealand New Zealand +4
Employees 3
Social

Get notified when CuroNZ moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About CuroNZ

CuroNZ is a biotech startup with a focus on innovative therapies for refractory epilepsies and challenging encephalopathies. The company has identified neurologically active peptide drug candidates called Neuronal Regeneration Peptides (NRPs) through phenotypic drug discovery screens using rodent brain tissue. Their lead clinical peptidomimetic NRP2945 is preparing for phase 2 trials in adults with drug-resistant Temporal Lobe Epilepsy and has been designated as an orphan drug for pediatric encephalopathy (Lennox-Gastaut Syndrome). NRPs have the potential to be a high impact drug due to their unique mechanisms of action, neuroregenerative and neuroprotective properties, as well as their ability to enhance memory consolidation and retrieval. CuroNZ's drug, NRP2945, shows promise in targeting various neurological disorders, such as ALS and childhood encephalopathies, by regulating differential protein expression of GABA A receptors. The company also aims to develop a follow-up compound to address larger neurological diseases like Alzheimer's, progressive MS, and dementia where the GABAergic system requires recalibration for symptom alleviation and regeneration. Since its establishment in 2010, CuroNZ has been steadily advancing its drug development programs, and its potential impact in the neurology therapeutics market is noteworthy. This offers a compelling investment opportunity for venture capital firms seeking to support groundbreaking advancements in CNS drug development.

Taxonomy: Biotech, Neurology, Drug Development, Clinical Trials, Orphan Drug Development, Neuroregenerative Therapies, GABA A Receptors, Epilepsy Treatment, Encephalopathy, Peptide Drugs, Phenotypic Drug Discovery, Neurological Disorders, Memory Improvement, Anxiety Treatment, Motor Diseases

No funding data available for CuroNZ yet.

Get notified when CuroNZ raises funding

CuroNZ Alternatives & Competitors

CuroNZ vs
SciTech Development, Inc.
SciTech Development, Inc. United States

SciTech Development is a Specialty Pharmaceutical Company dedicated to advancing breakthrough cancer...

Series Unknown
8 employees
Biotechnology, Life Sciences
CuroNZ vs
Phanes Therapeutics, Inc.
Phanes Therapeutics, Inc. United States

At Phanes, we bring innovation that illuminates the path to cure.

Unknown
29 employees
Biotechnology
CuroNZ vs
iniuva
iniuva Germany

we. fight. misfolding.

5 employees
Biotechnology, Health Care

FAQ About CuroNZ

Innovative biotech with CNS clinical drug
CuroNZ was founded in 2010.
CuroNZ is headquartered in New Zealand.
CuroNZ has approximately 3 employees.
Top alternatives and competitors to CuroNZ include SciTech Development, Inc., Phanes Therapeutics, Inc., iniuva, Vastu Vihar Biotech Pvt. Ltd., Bionure. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
CuroNZ and SciTech Development, Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors CuroNZ and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

Start Tracking — Free

One analytics cookie (Google Analytics). Cookie Policy